Julia P. Dunn

6.1k total citations · 5 hit papers
55 papers, 1.6k citations indexed

About

Julia P. Dunn is a scholar working on Physiology, Endocrinology, Diabetes and Metabolism and Pharmacology. According to data from OpenAlex, Julia P. Dunn has authored 55 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Physiology, 21 papers in Endocrinology, Diabetes and Metabolism and 16 papers in Pharmacology. Recurrent topics in Julia P. Dunn's work include Pharmacology and Obesity Treatment (16 papers), Diet and metabolism studies (16 papers) and Diabetes Treatment and Management (15 papers). Julia P. Dunn is often cited by papers focused on Pharmacology and Obesity Treatment (16 papers), Diet and metabolism studies (16 papers) and Diabetes Treatment and Management (15 papers). Julia P. Dunn collaborates with scholars based in United States, Australia and United Kingdom. Julia P. Dunn's co-authors include Naji N. Abumrad, Pamela A. Marks–Shulman, Robyn A. Tamboli, Irene D. Feurer, James M. Isbell, Erik N. Hansen, Jabbar Saliba, Robert Kessler, Josef Bednařík and Shubhada Jagasia and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and Diabetes Care.

In The Last Decade

Julia P. Dunn

50 papers receiving 1.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity

2024 273 citations Atul Malhotra, Ronald R. Grunstein et al. New England Journal of Medicine profile →
Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes

2023 120 citations Chrisanthi A. Karanikas, Julia P. Dunn et al. Diabetes Care profile →
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

2025 95 citations Deborah B. Horn, Clare J. Lee et al. New England Journal of Medicine profile →
Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial

2024 40 citations Atul Malhotra, Josef Bednařík et al. profile →
Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight

2025 21 citations Michelle Look, Julia P. Dunn et al. Diabetes Obesity and Metabolism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julia P. Dunn United States	18	733	615	546	323	294	55	1.6k
Cynthia-Michelle Borg United Kingdom	11	1.2k 1.6×	490 0.8×	1.1k 2.0×	179 0.6×	775 2.6×	21	1.9k
Dorte Lindqvist Hansen Denmark	23	1.4k 1.9×	1.2k 2.0×	1.7k 3.2×	295 0.9×	379 1.3×	44	2.5k
Per Grybäck Sweden	19	646 0.9×	500 0.8×	532 1.0×	138 0.4×	676 2.3×	43	1.7k
Blanca Oliván United States	8	1.0k 1.4×	680 1.1×	1.2k 2.1×	124 0.4×	255 0.9×	8	1.6k
Natasha C. Bergmann Denmark	17	238 0.3×	764 1.2×	362 0.7×	214 0.7×	121 0.4×	31	1.2k
Joy C. Bunt United States	24	1.0k 1.4×	643 1.0×	356 0.7×	149 0.5×	399 1.4×	42	2.4k
Sílvia Delgado-Aros United States	23	723 1.0×	213 0.3×	1.1k 1.9×	118 0.4×	218 0.7×	48	2.1k
Cynthia Buffington United States	22	880 1.2×	334 0.5×	978 1.8×	141 0.4×	160 0.5×	71	1.9k
Marie‐France Kong United Kingdom	19	400 0.5×	664 1.1×	324 0.6×	97 0.3×	106 0.4×	47	1.3k
Esben Thyssen Vestergaard Denmark	22	689 0.9×	422 0.7×	207 0.4×	37 0.1×	604 2.1×	72	1.5k

Countries citing papers authored by Julia P. Dunn

Since Specialization

Citations

This map shows the geographic impact of Julia P. Dunn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia P. Dunn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia P. Dunn more than expected).

Fields of papers citing papers by Julia P. Dunn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julia P. Dunn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia P. Dunn. The network helps show where Julia P. Dunn may publish in the future.

Co-authorship network of co-authors of Julia P. Dunn

This figure shows the co-authorship network connecting the top 25 collaborators of Julia P. Dunn. A scholar is included among the top collaborators of Julia P. Dunn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julia P. Dunn. Julia P. Dunn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Galindo, Rodolfo J., Alice Cheng, Minrong Ai, et al.. (2025). Insights into the Mechanism of Action of Tirzepatide: A Narrative Review. Diabetes Therapy. 17(1). 19–40. 1 indexed citations

Horn, Deborah B., Scott Kahan, Rachel L. Batterham, et al.. (2025). Time to weight plateau with tirzepatide treatment in the SURMOUNT ‐1 and SURMOUNT ‐4 clinical trials. Clinical Obesity. 15(3). e12734–e12734. 3 indexed citations

Look, Michelle, Julia P. Dunn, Robert F. Kushner, et al.. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight. Diabetes Obesity and Metabolism. 27(5). 2720–2729. 21 indexed citations breakdown →

Mamas, Mamas, Harold Bays, Rui Li, et al.. (2025). Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial. European Heart Journal Open. 5(5). oeaf117–oeaf117.

Ard, Jamy D., Lee M. Kaplan, Rekha B. Kumar, et al.. (2025). Perspectives on Obesity Management and the Use of Anti-Obesity Medicine from US Employees and Employers: Results from the OBSERVE Study. Population Health Management. 28(3). 150–160.

Shukla, Alpana P., et al.. (2025). Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial. Diabetes Obesity and Metabolism. 28(1). 452–462.

Tchang, Beverly G., Adam Stefański, Luis‐Emilio García‐Pérez, et al.. (2025). Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity. 33(5). 851–860. 1 indexed citations

Gudzune, Kimberly A., Lee M. Kaplan, Scott Kahan, et al.. (2024). Weight-Reduction Preferences Among OBSERVE Study Participants With Obesity or Overweight: Opportunities for Shared Decision-Making. Endocrine Practice. 30(10). 917–926. 3 indexed citations

Malhotra, Atul, Ronald R. Grunstein, Susan Redline, et al.. (2024). Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. New England Journal of Medicine. 391(13). 1193–1205. 273 indexed citations breakdown →

10.

Hunter, Theresa, et al.. (2024). #1704946 Improvements in Physical Functioning Among Participants With Obesity With Limitations in Physical Function at Baseline: Results from SURMOUNT-1 and SURMOUNT-2 Trials. Endocrine Practice. 30(5). S70–S70. 2 indexed citations

11.

Malhotra, Atul, Josef Bednařík, Julia P. Dunn, et al.. (2023). 0567 Tirzepatide for the Treatment of OSA: Rationale and Design of the SURMOUNT-OSA Phase 3 Trial. SLEEP. 46(Supplement_1). A249–A250. 4 indexed citations

12.

Kan, Hong, Jay Bae, Julia P. Dunn, et al.. (2023). Real-world primary nonadherence to antiobesity medications. Journal of Managed Care & Specialty Pharmacy. 29(10). 1099–1108. 8 indexed citations

13.

Dunn, Julia P., Naji N. Abumrad, Robert Kessler, et al.. (2017). Caloric Restriction‐Induced Decreases in Dopamine Receptor Availability are Associated with Leptin Concentration. Obesity. 25(11). 1910–1915. 12 indexed citations

14.

Whitlock, Anna E. Garcia, Robyn A. Tamboli, Raul S. González, et al.. (2015). Lipoprotein Profiles in Class III Obese Caucasian and African American Women with Nonalcoholic Fatty Liver Disease. PLoS ONE. 10(11). e0142676–e0142676. 13 indexed citations

15.

Dunn, Julia P., Robert Kessler, Irene D. Feurer, et al.. (2012). Relationship of Dopamine Type 2 Receptor Binding Potential With Fasting Neuroendocrine Hormones and Insulin Sensitivity in Human Obesity. Diabetes Care. 35(5). 1105–1111. 113 indexed citations

16.

Hansen, Erik N., Robyn A. Tamboli, James M. Isbell, et al.. (2011). Role of the foregut in the early improvement in glucose tolerance and insulin sensitivity following Roux-en-Y gastric bypass surgery. American Journal of Physiology-Gastrointestinal and Liver Physiology. 300(5). G795–G802. 64 indexed citations

17.

Dunn, Julia P., Ronald L. Cowan, Nora D. Volkow, et al.. (2010). Decreased dopamine type 2 receptor availability after bariatric surgery: Preliminary findings. Brain Research. 1350. 123–130. 119 indexed citations

18.

Dunn, Julia P., Mary Margaret Huizinga, Raphael See, & Waleed N. Irani. (2009). Choice of Imaging Modality in the Assessment of Coronary Artery Disease Risk in Extreme Obesity. Obesity. 18(1). 1–6. 12 indexed citations

19.

Perkins, Jennifer M., Julia P. Dunn, & Shubhada Jagasia. (2007). Perspectives in Gestational Diabetes Mellitus: A Review of Screening,Diagnosis, and Treatment. Clinical Diabetes. 25(2). 57–62. 78 indexed citations

20.

Davis, Stephen N. & Julia P. Dunn. (2006). Hypoglycemia—The Major Barrier to Good Glycemic Control. US Endocrinology. 0(1). 2–2. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact